Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR1F | P30939 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30949526 | 1.00 | HTR6 (0.59) | HTR6KDM4EUBE2NL3MBTL1HTR1A | |
| SCHEMBL28090812 | 0.87 | HTR6 (0.47) | HTR6KDM4EUBE2NL3MBTL1HTR1A | |
| SCHEMBL4562485 | 0.87 | HTR6 (0.59) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5746143 | 0.86 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL29686864 | 0.86 | HTR6 (0.68) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL30285388 | 0.85 | HTR6 (0.58) | HTR6KDM4EUBE2NL3MBTL1HTR1A | |
| SCHEMBL3684432 | 0.85 | HTR6 (0.58) | HTR6KDM4EUBE2NL3MBTL1HTR1A | |
| SCHEMBL4560894 | 0.82 | HTR6 (0.56) | HTR6KDM4EUBE2NL3MBTL1HTR1A | |
| SCHEMBL505125 | 0.82 | HTR6 (0.56) | HTR6KDM4EUBE2NL3MBTL1HTR1A | |
| SCHEMBL10823230 | 0.82 | HTR6 (0.56) | HTR6KDM4EUBE2NL3MBTL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57142969-A | — | — | None | — | — | JP | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| WO-2025037871-A1 | TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR | 에스케이바이오팜 주식회사 | 2025-02-20 | — | — | WO | disclosed |
| CN-118451078-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| EP-2855456-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| EP-2855456-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| CN-104603127-B | Complement pathway modulators and uses thereof | 诺华股份有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9056874-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-9056874-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-9056874-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| EP-2855456-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013164802-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013164802-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-11-07 | — | — | US | disclosed |
| JP-S57142969-A | SUBSTITUTED INDOLE | NISSAN CHEM IND LTD | 1982-09-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | HTR6 3754/4885KDM4E 1896/4885UBE2N 404/4885 |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | HTR6 1085/4885KDM4E 4092/4885UBE2N 3977/4885 |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | HTR6 1085/4885KDM4E 4092/4885UBE2N 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.